Radiation safety assessment of the radiopharmaceutical «Albumin microspheres 5-10 μm, labeled with Re-188» during radiosynovectomy of the knee joint

«Radiation and Risk», 2025, vol. 34, No. 3, pp.98-115

DOI: 10.21870/0131-3878-2025-34-3-98-115

Authors

Khvostunov I.K. – Chief researcher., D. Sc., Biol. Contacts: 4 Korolyov str., Obninsk, Kaluga region, Russia, 249035. Tel.: (484) 399-73-92; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .
Krylov V.V. – Head of Dep., D. Sc. Med.
Petriev V.M. – Head of Dep., D. Sc., Biol.
Korovchuk O.N. – Researcher
Geraskina A.S – Researcher
Lugovaya A.V. – Radiologist
Petrosyan K.M. – Radiologist
Zheleznov A.A. – Clin. resident
Ivanov S.A. – Director, Corr. Member of RAS, MD, Prof. of RUDN University Dep. A. Tsyb MRRC.
Kaprin A.D. – General Director, Director of P. Hertsen MORI, Head of RUDN University Dep., Academician of RAS, MD, Prof. NMRRC.
¹ A. Tsyb MRRC, Obninsk
² Peoples' Friendship University of Russia named after Patrice Lumumba, Moscow
³ NMRRC, Obninsk
⁴ P. Hertsen MORI, Moscow

Abstract

Radiosynovectomy of the knee joint may be accompanied by side radiation effects on the patient’s healthy organs and tissues, which must be correctly taken into account for the further introduction of this method into widespread practice. The aim of the study is to evaluate the radiation safety of the radiopharmaceutical “Albumin microspheres 5-10 μm labeled with ¹⁸⁸Re” (“AMS 5-10 μm, ¹⁸⁸Re”) for patients suffering from chronic synovitis of the knee joints, resistant to standard therapy. A cytoge-netic examination was carried out on 23 patients (12 men and 11 women) suffering from recurrent synovitis of the knee joints, resistant to standard therapy, including intra-articular administration of glucocorticoids. The examined patients received therapy with the administration of 370, 555, 740 and 925 MBq of radiopharmaceutical “AMS 5-10 μm, ¹⁸⁸Re” into one knee joint. Side radiation effects were investigated using induction of chromosomal aberrations in peripheral blood lymphocytes. A total of 66 blood samples (BS) were analyzed. BSs were taken from all patients before administration (control, 23 BS) and then 1 day (1 BS), 3 days (22 BS), 23 days (5 BS) and 28 days (15 BS) after injection. For biological dosimetry based on the frequency of aberrations, we used our own calibration dose dependence in the form of a linear-quadratic model, taking into account effect of dose rate. The results of a cytogenetic examination showed that the frequency of chromosomal aberrations ob-served after administration of radiopharmaceutical slightly exceeds control and does not depend on the value of the introduced activity in the range of 370-925 MBq. The side effects of radiation from the administration of radiopharmaceutical are safe, since the frequency of induced chromosomal aberrations does not exceed the spontaneous level in healthy donors. Biodosimetry assessment of the whole body adverse dose in the examined patients varies within the range of 104-182 mGy with an upper 95% confidence limit in the range of 410-521 mGy. The results of the study showed that side radiation exposure during radiosynovectomy with radiopharmaceutical “AMS 5-10 μm, ¹⁸⁸Re” does not pose a danger, since the adverse dose does not exceed the exposure from natural background radiation.

Key words
radiation safety, radiosynovectomy, radiopharmaceutical, ¹⁸⁸Re, albumin microspheres, blood lymphocytes, chromosome aberrations, radiobiology, nuclear medicine.

References

1. Kampen W.U., Boddenberg-Pätzold B., Fischer M., Gabriel M., Klett R., Konijnenberg M., Kresnik E., Lellouche H., Paycha F., Terslev L., Turkmen C., van der Zant F., Antunovic L., Panagiotidis E., Gnanasegaran G., Kuwert T., Van den Wyngaert T. The EANM guideline for radiosynoviorthesis. Eur. J. Nucl. Med. Mol. Imaging, 2022, vol. 49, no. 2, pp. 681-708.

2. Ahmad I., Nisar H. Dosimetry perspectives in radiation synovectomy. Phys. Med., 2018, vol. 47, no. 1, pp. 64-72.

3. Knut L. Radiosynovectomy in the therapeutic management of arthritis. World. J. Nucl. Med., 2015, vol. 14, no. 1, pp. 10-15.

4. Gazda A., Ćwikła J., Kołodziejczyk B., Szczygielska I., Hernik E., Gietka P., Rutkowska-Sak L. The use of radiosynovectomy in patients with juvenile idiopathic arthritis. Assessment of treatment efficacy and safety. Reumatologia, 2021, vol. 59, no. 4, pp. 219-229.

5. Balabanova R.M., Olyunin Yu.A., Lila A.M. Radioisotope synovectomy in the treatment of patients with rheumatoid arthritis. Sovremennaya revmatologiya – Modern Rheumatology Journal, 2019, vol. 13, no. 1, pp. 101-107. (In Russian).

6. Liepe K., Krylov V.V. Radiosynoviorthesis in the treatment of inflammatory joint diseases. Nauchno-prakticheskaya revmatologia – Rheumatology Science and Practice, 2013, vol. 51, no. 6, pp. 714-720. (In Russian).

7. Cytogenetic dosimetry: applications in preparedness for and response to radiation emergencies. Vienna, IAEA, 2011. 247 p.

8. Khvostunov I.K., Saenko V.A., Krylov V.V., Rodichev A.A., Yamashita S. Cytogenetic biodosimetry and dose-rate effect after radioiodine therapy for thyroid cancer. Radiat. Environ. Biophys., 2017, vol. 56, no. 3, pp. 213-226.

9. Sevan’kaev A.V., Khvostunov I.K., Snigireva G.P., Novickaya N.N., Antoshchina M.M., Fesenko E.V., Vorobcova I.E., Neronova E.G., Domracheva E.V., Nugis V.Yu., Govorun R.D., Handogina E.K. Comparative analysis of the results of cytogenetic examinations of control groups of individuals in various domestic laboratories. Radiatsionnaya biologiya. Radioekologiya – Radiation Biology. Radioecology, 2013, vol. 53, no. 1, pp. 5-24. (In Russian).

10. Stepchenkova E.D., Tishchenko V.K., Vlasova O.P., Petriev V.M., Legkodimova N.S., Krylov V.V., Fedorova A.V., Kuzenkova E.A., Ostroukhoff A.A., Shegai P.V. Distribution of activity in the blood and urine of patients receiving systemic therapy with a radiopharmaceutical with 177Lu and local (intra-articular) therapy with a radiopharmaceutical with 188Re. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya. Regulyatornyye issledovaniya i ekspertiza lekarstvennykh sredstv – Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation, 2022, vol. 12, no. 4, pp. 404-414. (In Russian).

11. Dale R.G. Radiation repair models for clinical application. Br. J. Radiol., 2019, vol. 92, no. 1093, pp. 20180070. DOI: 10.1259/bjr.20180070.

12. Higueras M., González J.E., Di Giorgio M., Barquinero J.F. A note on Poisson goodness-of-fit tests for ionizing radiation induced chromosomal aberration samples. Int. J. Radiat. Biol., 2018, vol. 94, no. 7, pp. 656-663.

13. Klett R., Schnurbus-Duhs A., Mödder G., Schmid E., Voth M. Biological dosimetry after radiosynoviorthesis with rhenium-186 sulphide and erbium-169 citrate. Nuklearmedizin, 2012, vol. 51, no. 1, pp. 17-25.

14. Voth M., Klett R., Lengsfeld P., Stephan G., Schmid E. Biological dosimetry after yttrium-90 citrate colloid radiosynoviorthesis. Nuklearmedizin, 2006, vol. 45, no. 5, pp. 223-228.

15. Lloyd D.C., Reeder E.J. Chromosome aberrations and intra-articular yttrium-90. Lancet, 1978, vol. 311, no. 8064, pp. 617.

16. Stephan G., Pressl S. Chromosomal aberrations in peripheral lymphocytes from healthy subjects as detected in first cell division. Mutat. Res., 1999, vol. 446, no. 2, pp. 231-237.

17. Klett R., Puille M., Matter H.P., Steiner D., Stürz H., Bauer R. Activity leakage and radiation exposure in radiation synovectomy of the knee: influence of different therapeutic modalities. Z. Rheumatol., 1999, vol. 58, no. 4, pp. 207-212.

18. Jang S., Lee Y., Seo S., Jin Y.W., Lee W.J. Rogue cell-like chromosomal aberrations in peripheral blood lymphocytes of interventional radiologists: a case study. Mutat. Res. Genet. Toxicol. Environ. Mutagen., 2020, vol. 856-857, pp. 503234. DOI: 10.1016/j.mrgentox.2020.503234.

19. Manil L., Voisin P., Aubert B., Guerreau D., Verrier P., Lebègue L., Wargnies J.P., Di Paola M., Barbier Y., Chossat F., Menkes C.J., Tébib J., Devaux J.Y., Kahan A. Physical and biological dosimetry in patients undergoing radiosynoviorthesis with erbium-169 and rhenium-186. Nucl. Med. Commun., 2001, vol. 22, no. 4, pp. 405-416.

20. Grmek M., Milcinski M., Fettich J., Brecelj J. Radiation exposure of hemophiliacs after radiosynoviorthesis with 186Re colloid. Cancer Biother. Radiopharm., 2007, vol. 22, no. 3, pp. 417-422.

21. Schmid E., Selbach H.-J., Voth M., Pinkert J., Gildehaus F.J., Klett R., Haney M. The effect of the beta-emitting yttrium-90 citrate on the dose–response of dicentric chromosomes in human lymphocytes: a basis for biological dosimetry after radiosynoviorthesis. Radiat. Environ. Biophys., 2006, vol. 45, no. 2, pp. 93-98.

22. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid, 2009, vol. 19, no. 12, pp. 1381-1391.

Full-text article (in Russian)